Metformin Alleviates Epirubicin-Induced Endothelial Impairment by Restoring Mitochondrial Homeostasis

Qi Sun, Huiling Jia, Shuo Cheng, Yujuan Wang, Jun WangInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This study reveals that the chemotherapy drug epirubicin damages vascular endothelial cells by disrupting mitochondrial function and homeostasis, leading to DNA damage and increased inflammatory markers. The researchers demonstrate that metformin, a common diabetes drug, can protect these cells by restoring mitochondrial balance, specifically by upregulating TFAM and downregulating DRP1 through the calcineurin/TFEB pathway.

What Problem Does This Paper Address?

Anthracyclines, a class of chemotherapy drugs like epirubicin and doxorubicin, are vital for treating various cancers. However, they are notorious for causing cardiotoxicity, a dose-dependent side effect that can lead to heart failure. While much research has focused on the direct impact of these drugs on cardiomyocytes, the role of vascular endothelial injury in this cardiotoxicity has become increasingly recognized. Epirubicin, in particular, can damage endothelial cells, contributing to chronic vascular diseases. Understanding the mechanisms behind this endothelial damage and identifying protective strategies is crucial for improving patient outcomes and mitigating long-term cardiovascular risks associated with chemotherapy. This paper aims to elucidate how epirubicin harms endothelial cells at the mitochondrial level and to explore metformin's protective role in this context.

Methods

The study employed a combination of in vitro techniques using human umbilical vein endothelial cells (HUVEC). Key methods included:

  • Western Blotting: To assess the expression levels of various proteins involved in mitochondrial biogenesis (TFAM, PGC1α), mitochondrial dynamics (DRP1, p-DRP1, OPA1, MFN1, MFN2), and signaling pathways (Calcineurin, TFEB).
  • ELISA (Enzyme-Linked Immunosorbent Assay): To quantify the release of Angiotensin II (Ang II), a marker of endothelial dysfunction.
  • ROS Detection: Using the DCFH-DA probe to measure intracellular reactive oxygen species (ROS) levels, a key indicator of oxidative stress.
  • DNA Damage Assessment: Detecting phosphorylated H2A.X (γ-H2A.X) as a marker for DNA double-strand breaks.
  • Mitochondrial Morphology Analysis: Using MitoTracker Green staining to visualize and quantify mitochondrial fragmentation and tubular structures.
  • siRNA Transfection: To specifically knock down the expression of key genes like TFAM and TFEB to investigate their roles in epirubicin-induced damage and metformin's protective effects.
  • Pharmacological Inhibition: Using Mdivi-1 (a DRP1 inhibitor) and Cyclosporin A (CsA, a calcineurin inhibitor) to probe specific molecular pathways.

Datasets

Not discussed in the paper. The study primarily relies on in vitro experiments using cultured HUVEC cells.

Key Insights and Ideas

  • Mitochondrial Homeostasis as a Central Target: The paper strongly suggests that epirubicin's damage to endothelial cells is primarily mediated by disrupting mitochondrial function and homeostasis, rather than solely through direct DNA damage.
  • Metformin's Multifaceted Protection: Metformin doesn't just offer a single protective mechanism; it appears to act on multiple fronts, including reducing ROS, mitigating DNA damage, and normalizing Ang II levels.
  • TFAM as a Key Player in Epirubicin Resistance: The study highlights TFAM's critical role in protecting endothelial cells from epirubicin-induced DNA damage. Metformin's ability to boost TFAM expression is a significant finding.
  • Mitochondrial Dynamics are Crucial: Epirubicin induces mitochondrial fragmentation by promoting fission (via DRP1) and inhibiting fusion (via OPA1 and MFN1). Metformin's ability to partially reverse this fragmentation is a key protective mechanism.
  • The Calcineurin/TFEB Pathway as the Master Regulator: The research pinpoints the calcineurin/TFEB pathway as the central signaling hub through which metformin exerts its protective effects, influencing both TFAM expression and mitochondrial dynamics.

Key Results

  • Epirubicin treatment in HUVEC cells led to significant increases in DNA double-strand breaks (DSB), ROS production, and Ang II release.
  • Pretreatment with metformin significantly attenuated these epirubicin-induced damages.
  • Epirubicin treatment reduced TFAM expression and caused mitochondrial fragmentation. Metformin pretreatment partially restored TFAM levels and mitochondrial morphology.
  • Knockdown of TFAM partially reversed metformin's protective effect against epirubicin-induced DNA damage.
  • Inhibition of mitochondrial fission with Mdivi-1 reduced DSB formation and increased TFAM expression.
  • Epirubicin increased DRP1 expression and phosphorylation (Ser616), while decreasing OPA1 and MFN1. Metformin partially reversed these changes.
  • Metformin increased calcineurin and TFEB protein expression, which were downregulated by epirubicin.
  • Knockdown of TFEB attenuated metformin's protective effects against epirubicin-induced DNA damage and reversed the reduction in DRP1 expression.

Limitations and Future Work

  • In Vitro Model: The study was conducted using HUVEC cells in vitro. While informative, these findings need to be validated in in vivo models and human studies to confirm their clinical relevance.
  • Specific Mechanisms of Metformin: While the calcineurin/TFEB pathway is identified, the precise upstream mechanisms by which metformin activates calcineurin and subsequently TFEB require further investigation.
  • Clinical Translation: The authors suggest that metformin could be beneficial in reducing epirubicin-induced vascular endothelial damage and potentially enhancing antitumor efficacy. Future work should focus on clinical trials to assess metformin's efficacy and safety in cancer patients undergoing epirubicin treatment.
  • Broader Anthracycline Effects: The study focused on epirubicin. Further research could explore whether metformin offers similar protection against other anthracyclines like doxorubicin.

Summary updated

Abstract

Vascular endothelial injury is important in anthracycline-induced cardiotoxicity. Anthracyclines seriously damage the mitochondrial function and mitochondrial homeostasis. In this study, we investigated the damage of epirubicin to vascular endothelial cells and the protective role of metformin from the perspective of mitochondrial homeostasis. We found that epirubicin treatment resulted in DNA double-strand breaks (DSB), elevated reactive oxygen species (ROS) production, and excessive Angiotensin II release in HUVEC cells. Pretreatment with metformin significantly mitigated the injuries caused by epirubicin. In addition, inhibited expression of Mitochondrial transcription factor A (TFAM) and increased mitochondria fragmentation were observed in epirubicin-treated cells, which were partially resumed by metformin pretreatment. In epirubicin-treated cells, knockdown of TFAM counteracted the attenuated DSB formation due to metformin pretreatment, and inhibition of mitochondrial fragmentation with Mdivi-1 decreased DSB formation but increased TFAM expression. Furthermore, epirubicin treatment promoted mitochondrial fragmentation by stimulating the expression of Dynamin-1-like protein (DRP1) and inhibiting the expression of Optic atrophy-1(OPA1) and Mitofusin 1(MFN1), which could be partially prevented by metformin. Finally, we found metformin could increase TFAM expression and decrease DRP1 expression in epirubicin-treated HUVEC cells by upregulating the expression of calcineurin/Transcription factor EB (TFEB). Taken together, this study provided evidence that metformin treatment was an effective way to mitigate epirubicin-induced endothelial impairment by maintaining mitochondrial homeostasis.
BibTeX
@article{sun2022metformin,
  author = {Qi Sun and Huiling Jia and Shuo Cheng and Yujuan Wang and Jun Wang},
  title = {{Metformin Alleviates Epirubicin-Induced Endothelial Impairment by Restoring Mitochondrial Homeostasis}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms24010343},
}
Figure